163 related articles for article (PubMed ID: 7600046)
1. The use of recombinant human erythropoietin in predialysis patients.
Besarab A; Ross RP; Nasca TJ
Curr Opin Nephrol Hypertens; 1995 Mar; 4(2):155-61. PubMed ID: 7600046
[TBL] [Abstract][Full Text] [Related]
2. Impact of recombinant human erythropoietin treatment on left ventricular hypertrophy and cardiac function in dialysis patients.
Massimetti C; Pontillo D; Feriozzi S; Costantini S; Capezzuto A; Ancarani E
Blood Purif; 1998; 16(6):317-24. PubMed ID: 10343078
[TBL] [Abstract][Full Text] [Related]
3. Effects of human recombinant erythropoietin on anaemia, systemic haemodynamics and renal function in predialysis renal failure patients.
Onoyama K; Kumagai H; Takeda K; Shimamatsu K; Fujishima M
Nephrol Dial Transplant; 1989; 4(11):966-70. PubMed ID: 2516888
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular effects of recombinant human erythropoietin in predialysis patients.
Portolés J; Torralbo A; Martin P; Rodrigo J; Herrero JA; Barrientos A
Am J Kidney Dis; 1997 Apr; 29(4):541-8. PubMed ID: 9100042
[TBL] [Abstract][Full Text] [Related]
5. Treatment of renal anemia with recombinant human erythropoietin.
Macdougall IC
Curr Opin Nephrol Hypertens; 1992 Dec; 1(2):210-9. PubMed ID: 1345620
[TBL] [Abstract][Full Text] [Related]
6. Cost of treating predialysis patients with recombinant human erythropoietin.
Durand-Zaleski I; Goldfarb B; Blum-Boisgard C; Drüeke T; Kreis H
Nephrol Dial Transplant; 1993; 8(4):311-4. PubMed ID: 8390004
[TBL] [Abstract][Full Text] [Related]
7. Body fluid spaces and blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin.
Abraham PA; Opsahl JA; Keshaviah PR; Collins AJ; Whalen JJ; Asinger RW; McLain LA; Hanson G; Davis MG; Halstenson CE
Am J Kidney Dis; 1990 Nov; 16(5):438-46. PubMed ID: 2239934
[TBL] [Abstract][Full Text] [Related]
8. The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind, placebo-controlled trial.
Kleinman KS; Schweitzer SU; Perdue ST; Bleifer KH; Abels RI
Am J Kidney Dis; 1989 Dec; 14(6):486-95. PubMed ID: 2688405
[TBL] [Abstract][Full Text] [Related]
9. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. The US Recombinant Human Erythropoietin Predialysis Study Group.
Am J Kidney Dis; 1991 Jul; 18(1):50-9. PubMed ID: 2063855
[TBL] [Abstract][Full Text] [Related]
10. Erythropoietin treatment in children with renal failure.
Van Damme-Lombaerts R; Herman J
Pediatr Nephrol; 1999 Feb; 13(2):148-52. PubMed ID: 10229005
[TBL] [Abstract][Full Text] [Related]
11. Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilar epoetin-alfa in hemodialysis patients with anemia.
Thanakitcharu P; Siriwiwatanakul N
J Med Assoc Thai; 2007 Dec; 90(12):2574-86. PubMed ID: 18386706
[TBL] [Abstract][Full Text] [Related]
12. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin.
Silberberg J; Racine N; Barre P; Sniderman AD
Can J Cardiol; 1990; 6(1):1-4. PubMed ID: 2138048
[TBL] [Abstract][Full Text] [Related]
13. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients.
Roth D; Smith RD; Schulman G; Steinman TI; Hatch FE; Rudnick MR; Sloand JA; Freedman BI; Williams WW; Shadur CA
Am J Kidney Dis; 1994 Nov; 24(5):777-84. PubMed ID: 7977319
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of recombinant human erythropoietin in predialysis patients. Austrian Multicenter Study Group of r-HuEPO in Predialysis Patients.
Nephron; 1992; 61(4):399-403. PubMed ID: 1501735
[TBL] [Abstract][Full Text] [Related]
15. Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients.
Abraham PA; Opsahl JA; Rachael KM; Asinger R; Halstenson CE
Am J Nephrol; 1990; 10(2):128-36. PubMed ID: 2349956
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacokinetics and clinical effect of recombinant human erythropoietin on the anemia of predialysis patients].
Yamazaki C; Itoh A; Yamamoto N; Kobayashi M; Watanabe Y; Sakamoto N
Nihon Jinzo Gakkai Shi; 1992 Jun; 34(6):701-10. PubMed ID: 1479710
[TBL] [Abstract][Full Text] [Related]
17. The effects of maintenance recombinant human erythropoietin therapy on ambulatory blood pressure recordings: conventional, Doppler, and tissue Doppler echocardiographic parameters.
Kirkpantur A; Kahraman S; Yilmaz R; Arici M; Altun B; Erdem Y; Yasavul U; Turgan C
Artif Organs; 2005 Dec; 29(12):965-72. PubMed ID: 16305652
[TBL] [Abstract][Full Text] [Related]
18. Treatment of renal anemia by erythropoietin substitution. The effects on the cardiovascular system.
Radermacher J; Koch KM
Clin Nephrol; 1995 Nov; 44 Suppl 1():S56-60. PubMed ID: 8608665
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human erythropoietin therapy in children on dialysis.
Jabs K; Harmon WE
Adv Ren Replace Ther; 1996 Jan; 3(1):24-36. PubMed ID: 8620365
[TBL] [Abstract][Full Text] [Related]
20. Evidence for amelioration of endothelial cell dysfunction by erythropoietin therapy in predialysis patients.
Kuriyama S; Hopp L; Yoshida H; Hikita M; Tomonari H; Hashimoto T; Sakai O
Am J Hypertens; 1996 May; 9(5):426-31. PubMed ID: 8735172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
